Shonali Midha, MD, Dana-Farber Cancer Institute, Boston, MA, discusses a study which used a global survey to analyze practice patterns for managing the side effects of BCMA-targeting immunotherapies, such as bispecific antibodies and CAR-T cells, in patients with multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.